Lauren Hackett named deputy director of administration at Albert Einstein Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Lauren Hackett was named deputy director of administration of Albert Einstein Cancer Center and associate vice president of cancer medicine at Montefiore Medicine. 

Hackett, who is currently the chief operating officer at the Allen Institute, will assume these roles in August 2021.  

At AECC, Hackett will have oversight and authority over the administrative team and structure, running all aspects of its operations. A key part of her role is partnering with the senior leaders at AECC, Einstein, and Montefiore to align and implement strategic priorities across its cancer enterprise.  

As COO at the Allen Institute, a private, non-profit research institute, she led the institute through the COVID-19 pandemic and co-developed the institute’s diversity, equity, and inclusion initiative. She also partnered with colleagues to integrate scientific strategy and planning efforts throughout administration and operations teams across the institute.  

Table of Contents


Two Republican leaders in the House of Representatives have published a “framework” for reforming NIH—consolidating the agency’s 27 institutes and centers into 15—arguing that a fundamental rethinking of NIH’s structure would fix what they describe as a “system rife with stagnant leadership, as well as research duplication, gaps, and misconduct.”
“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon. 
On Sept. 24, 2002, the Oncologic Drugs Advisory Committee recommended an accelerated approval for AstraZeneca’s Iressa (gefitinib). The recommendation concluded a meeting where ODAC weighed whether the drug, an EGFR tyrosine kinase inhibitor, could benefit patients with resistant or refractory non-small cell lung cancer as a third-line therapy.